Goldman Sachs’s Utah Medical Products UTMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $595K | Sell |
8,627
-3,822
| -31% | -$254K | ﹤0.01% | 5589 |
|
|
2026
Q1 | $772K | Buy |
12,449
+1,416
| +13% | +$89.2K | ﹤0.01% | 5282 |
|
|
2025
Q4 | $617K | Buy |
11,033
+5,900
| +115% | +$342K | ﹤0.01% | 5468 |
|
|
2025
Q3 | $323K | Buy |
5,133
+242
| +5% | +$14.3K | ﹤0.01% | 5716 |
|
|
2025
Q2 | $278K | Sell |
4,891
-9,395
| -66% | -$511K | ﹤0.01% | 5479 |
|
|
2025
Q1 | $801K | Sell |
14,286
-495
| -3% | -$29.7K | ﹤0.01% | 4851 |
|
|
2024
Q4 | $909K | Buy |
14,781
+7,778
| +111% | +$503K | ﹤0.01% | 4883 |
|
|
2024
Q3 | $469K | Buy |
7,003
+3,898
| +126% | +$265K | ﹤0.01% | 5084 |
|
|
2024
Q2 | $207K | Sell |
3,105
-4,595
| -60% | -$313K | ﹤0.01% | 5250 |
|
|
2024
Q1 | $548K | Sell |
7,700
-26,812
| -78% | -$2.01M | ﹤0.01% | 4706 |
|
|
2023
Q4 | $2.91M | Sell |
34,512
-6,444
| -16% | -$534K | ﹤0.01% | 3624 |
|
|
2023
Q3 | $3.52M | Buy |
40,956
+100
| +0.2% | +$9.23K | ﹤0.01% | 3306 |
|
|
2023
Q2 | $3.81M | Sell |
40,856
-2,604
| -6% | -$245K | ﹤0.01% | 3344 |
|
|
2023
Q1 | $4.12M | Buy |
43,460
+2,465
| +6% | +$227K | ﹤0.01% | 3223 |
|
|
2022
Q4 | $4.12M | Buy |
40,995
+5
| +0% | +$456 | ﹤0.01% | 3341 |
|
|
2022
Q3 | $3.5M | Buy |
40,990
+10,232
| +33% | +$903K | ﹤0.01% | 3471 |
|
|
2022
Q2 | $2.64M | Buy |
30,758
+1,457
| +5% | +$124K | ﹤0.01% | 3804 |
|
|
2022
Q1 | $2.63M | Sell |
29,301
-4,019
| -12% | -$370K | ﹤0.01% | 3987 |
|
|
2021
Q4 | $3.33M | Sell |
33,320
-1,043
| -3% | -$106K | ﹤0.01% | 3794 |
|
|
2021
Q3 | $3.19M | Hold |
34,363
| – | – | ﹤0.01% | 3763 |
|
|
2021
Q2 | $2.92M | Buy |
34,363
+943
| +3% | +$81.6K | ﹤0.01% | 3851 |
|
|
2021
Q1 | $2.89M | Buy |
33,420
+10,427
| +45% | +$917K | ﹤0.01% | 3617 |
|
|
2020
Q4 | $1.94M | Buy |
22,993
+6,025
| +36% | +$514K | ﹤0.01% | 3755 |
|
|
2020
Q3 | $1.36M | Buy |
16,968
+14,489
| +584% | +$1.2M | ﹤0.01% | 3862 |
|
|
2020
Q2 | $220K | Sell |
2,479
-21
| -0.8% | -$1.88K | ﹤0.01% | 4751 |
|
|
2020
Q1 | $235K | Sell |
2,500
-1,654
| -40% | -$154K | ﹤0.01% | 4629 |
|
|
2019
Q4 | $448K | Buy |
4,154
+1,904
| +85% | +$193K | ﹤0.01% | 4564 |
|
|
2019
Q3 | $216K | Buy |
2,250
+18
| +0.8% | +$1.67K | ﹤0.01% | 4801 |
|
|
2019
Q2 | $214K | Buy |
+2,232
| New | +$188K | ﹤0.01% | 4764 |
|
|
2018
Q4 | – | Sell |
-2,548
| Closed | -$240K | – | 5689 |
|
|
2018
Q3 | $240K | Buy |
2,548
+117
| +5% | +$11.2K | ﹤0.01% | 4819 |
|
|
2018
Q2 | $268K | Buy |
+2,431
| New | +$254K | ﹤0.01% | 4844 |
|
|
2017
Q2 | – | Sell |
-4,377
| Closed | -$273K | – | 6985 |
|
|
2017
Q1 | $273K | Buy |
+4,377
| New | +$276K | ﹤0.01% | 5531 |
|
Other funds holding UTMD
MA
Goldman Sachs's UTMD Position: Q2 2026 in Review
Goldman Sachs reduced its Utah Medical Products (UTMD) stake by 31% in Q2 2026, selling an estimated $254K and leaving 8,627 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #5589.
Goldman Sachs first reported a position in UTMD in Q1 2017 and has held it in 32 quarters since. The position peaked at $4.12M in Q4 2022. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.
- Goldman Sachs held 8,627 shares of Utah Medical Products worth $595K as of Q2 2026.
- Goldman Sachs sold 3,822 Utah Medical Products shares in Q2 2026, an estimated $254K.
- Utah Medical Products made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5589 holding.
- Goldman Sachs first reported a position in Utah Medical Products in Q1 2017 and has held it in 32 quarters since.
- Goldman Sachs's Utah Medical Products position peaked at $4.12M in Q4 2022.
- 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.